TCTMD Login - tctmd.com
TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
When the Time Comes to Stop Oral Anticoagulation: Options and …
Sep 28, 2021 · Oral anticoagulants can prevent thrombotic events and save lives in patients with atrial fibrillation (AF) and other conditions, but they don’t in and of themselves make patients feel better.
Cheaper Version of Tirzepatide for Weight Loss Now Available, …
Aug 28, 2024 · The manufacturer is selling single-dose vials of the drug via its online pharmacy at around $400 to $500 for a 4-week supply.
Injectable Semaglutide Shortage Forces Physicians to Pivot
Feb 5, 2024 · Shortages of injectable semaglutide (Novo Nordisk), sold under trade names Ozempic (for type 2 diabetes with or without established CVD) and Wegovy (for overweight or obesity), are forcing clinicians to look to alternatives when managing patients who …
Welcome to TCTMD | tctmd.com
Thank you for joining TCTMD, the leading community for interventional cardiovascular news and education and beyond. When you registered with us today, you joined tens of thousands of other clinicians and industry professionals around the world who utilize our platform to stay update-to-date on the latest developments in interventional cardiology and endovascular medicine.
‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry
Jan 10, 2020 · Several heart failure physicians, specifically those who treat patients with cardiomyopathy caused by transthyretin amyloidosis (ATTR-CM), are calling attention to the extraordinarily high price of tafamidis and tafamidis meglumine (Vyndamax and Vyndaqel; Pfizer), both of which received orphan drug designation and were approved by the US Food and Drug Administration in 2019.
Martin B. Leon, MD - TCTMD.com
Martin B. Leon, MD, is a Professor of Medicine at Columbia University Irving Medical Center in New York, NY, as well as Chief Innovation Officer and the Director of the Cardiovascular Data Science Center for the Division of Cardiology.
FDA Approves First New PET Imaging Tracer for Cardiac Testing in ...
Oct 2, 2024 · A new radioactive tracer for positron emission tomography (PET) myocardial perfusion imaging will soon be available in the United States, and it’s expected to facilitate substantial growth in such testing over the coming years.
SUMMIT Meets Primary Endpoint for Safety, Efficacy of Tirzepatide ...
Aug 1, 2024 · Patients who have heart failure with preserved ejection fraction (HFpEF) and obesity can be safely and effectively treated with tirzepatide (Mounjaro and Zepbound; Eli Lilly) through 2 years of follow-up, with topline data from the phase III SUMMIT trial showing the drug reduces heart failure events and improves other patient …
Interventional Complications 2024 - TCTMD.com
Aug 2, 2024 · TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.